Crinetics appoints Dana Pizzuti, M.D. as Chief Development Officer effective Sept 30, 2022

Crinetics Pharmaceuticals, Inc.

Dr. Pizzuti appointed CDO effective Sept 30, 2022; annual base salary $525,000 and target annual bonus of 40% of base.
She has over 30 years pharma experience, including leading regulatory at Gilead and Ascendis; helped secure marketing approvals for 15 drugs.
Expected equity grants: stock option for 230,000 shares (25% vest Sept 30, 2023, then 36 monthly) and 12,500 RSUs (vest March 30, 2023).
Signing bonus of $95,000 and relocation assistance; severance includes 9-12 months base salary depending on termination scenario.
Her appointment supports upcoming Phase 3 topline data for paltusotine in acromegaly and preparation of marketing authorization applications.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dana Pizzuti

Chief Development Officer

CRNX · Crinetics Pharmaceuticals, Inc.

Effective: 2022-09-30
Filed: October 3, 2022, 7:59 PM ET

On October 3, 2022, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Dana Pizzuti, M.D. as the Company’s Chief Development Officer, which was effective as of September 30, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dana Pizzuti was appointed as Chief Development Officer at Crinetics Pharmaceuticals, Inc..

Action: appointed
Role: Chief Development Officer

Exact text from the filing

On October 3, 2022, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Dana Pizzuti, M.D. as the Company’s Chief Development Officer, which was effective as of September 30, 2022.

View on SEC.gov

Crinetics Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-019164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.